ArticleJournal of translational medicine2015

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.

Juan Madoz-Gúrpide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.